Mitochondrial DNA and Cancer Epidemiology Workshop

Agenda

Day 1 - Thursday, September 7, 2006
8:30 a.m. – 9:00 a.m. Registration
9:00 a.m. – 9:10 a.m. Welcome Address
Deborah Winn, Ph.D.
Acting Associate Director of the Epidemiology and Genetics Research Program (EGRP), Division of Cancer Control and Population Sciences (DCCPS), National Cancer Institute (NCI), National Institutes of Health (NIH)
9:10 a.m. – 9:30 a.m. Charges to the Participants
Mukesh Verma, Ph.D.
Acting Branch Chief, Analytic Epidemiology Research Branch and Program Director, EGRP, DCCPS, NCI, NIH
9:30 a.m. – 10:00 a.m. Overview
Keshav K. Singh, Ph.D. (Chair of the Meeting)
Associate Professor, Department of Cancer Genetics, Roswell Park Cancer Institute
10:00 a.m. – 10:20 a.m. Breast Cancer Population Studies
Jeffrey A. Canter, M.D., M.P.H.
Investigator, Center for Human Genetics Research, Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center
10:20 a.m. – 10:40 a.m. Break
10:40 a.m. – 11:00 a.m. Mitochondrial Haplogroups and Cancer and Metabolic Diseases
Masashi Tanaka , M.D., Ph.D.
Research Director, Genomics for Longevity and Health, Tokyo Metropolitan Institute of Gerontology
11:00 a.m. – 11:20 a.m. Cytochrome C Oxidase Subunit I Mutations and Haplotype Predisposition in Prostate and Renal Cancer
John Petros, M.D.
Associate Professor, Department of Urology, Pathology and Laboratory Medicine and the Winship Cancer Institute, Emory University and the Atlanta VA Medical Center
11:20 a.m. – 11:40 a.m. Mitochondrial Correlation Microscopy in Single Cell Cancer Diagnosis
Paul L. Gourley, Ph.D.
Distinguished Member of Science Staff, Biomolecular Materials and Systems, Sandia National Laboratories
11:40 a.m. – 12:00 noon Biocavity Laser Spectroscopy of Cancer Cells and Genetic Forms of Mitochondrial Disease
Robert K. Naviaux, M.D., Ph.D. (Co-Chair of the Meeting)
Associate Professor, Department of Medicine, University of California, San Diego
12:00 noon – 1:30 p.m. Lunch
1:30 p.m. – 1:50 p.m. Skin Cancer mtDNA Mutation
James E. Sligh, M.D., Ph.D.
Assistant Professor, Division of Dermatology, Vanderbilt University Medical Center
1:50 p.m. – 2:10 p.m. The Role of mtDNA Alterations in Body Fluids in Diagnosing Cancer
Edward R. Sauter, M.D., Ph.D.
Professor, Department of Surgery, University of Missouri, Columbia
2:10 p.m. – 2:20 p.m. hMitChip3 and Mitochondrial Transcriptome in Melanoma
Yan Su, M.D., Ph.D.
Associate Professor of Biochemistry and Molecular Biology, Associate Director of Catherine Birch McCormick Genomics Center, The George Washington University Medical Center
2:20 p.m. – 2:40 p.m. Depletion of mtDNA in Prostate Cancer
Masahiro Higuchi, Ph.D.
Assistant Professor, Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences
2:40 p.m. – 3:00 p.m. Mitochondrial DNA Mutations and Reactive Oxygen Species Stress in Cancer Cells: Molecular Players and Clinical Implications
Peng Huang, M.D., Ph.D.
Associate Professor, Department of Molecular Pathology, The University of Texas M.D. Anderson Cancer Center
3:00 p.m. – 3:20 p.m. Break
3:20 p.m. – 5:30 p.m.

Discussion Panel Leaders
Konstantin Khrapko, Ph.D.
Assistant Professor, Department of Medicine, Beth Israel Medical Center, Harvard Medical School

Laurence N. Kolonel, M.D., Ph.D.
Director, Epidemiology Program, Cancer Research Center, University of Hawaii

Roberta B. Ness, M.D., Ph.D.
Professor and Chair, Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh

Alexander S. Parker, Ph.D., M.S.
Assistant Professor of Epidemiology, Department of Urology, Mayo Clinic College of Medicine

Peter G. Shields, M.D., Ph.D.
Georgetown University Lombardi Comprehensive Cancer Center

Mukesh Verma, Ph.D.
Acting Branch Chief, Analytic Epidemiology Research Branch and Program Director, EGRP, DCCPS, NCI, NIH

Discussion Questions

  • Are we ready to utilize mitochondrial DNA information in studying cancer epidemiology?
  • If not, what are the issues?
  • How will mitochondrial proteomic knowledge contribute toward understanding cancer etiology in the population sciences?
  • MitoChip (high-throughput).
  • Sensitivity, specificity of the assays to detect mutation.
  • Mitochondrial DNA: sample preparation.
  • How much sample is needed? Which samples are best for mutation analysis?
  • Origin of mitochondrial mutation: stem cells?
  • Do somatic mtDNA mutations actually provoke pathological states, or should they be considered epiphenomena? (Somatic mtDNA mutations: the chicken or the egg?)
  • Are we there yet? Use in clinic.
  • Identifying a cohort of patients with suspected mitochondrial disorders is a challenge.
  • Founder effects?
  • Are mutations causative or merely a reflection of nuclear instability?
  • Are these processes independent events?
  • Mitochondrial haplotypes.
5:30 p.m. Adjourn
 
Day 2 – Friday, September 8, 2006
8:30 a.m. – 9:00 a.m. Registration
9:00 a.m. – 9:20 a.m. The Origins of mtDNA Mutations
William Copeland, Ph.D.
Senior Investigator, Laboratory of Molecular Genetics, National Institute of Environmental Health Sciences, NIH
9:20 a.m. – 9:40 a.m. mtDNA Involvement in Aging/Longevity and Age-Related Diseases
Claudio Franceschi, M.D., Ph.D.
Professor, Department of Experimental Pathology, University of Bologna, Italy
9:40 a.m. – 10:00 a.m. Somatic mtDNA Mutations and Germline mtDNA Polymorphisms in Cancer
Lee-Jun C. Wong, Ph.D.
Professor, Department of Molecular and Human Genetics and Director, Mitochondrial Diagnostic Laboratory, Baylor College of Medicine
10:00 a.m. – 10:20 a.m. Break
10:20 a.m. – 12:30 p.m. Recommendations Presented to the Group by the Chair and Co-Chair
12:30 p.m. Adjourn